-+ 0.00%
-+ 0.00%
-+ 0.00%

Neumora Q1 FY26 net loss narrows to $53.5 million

PUBT·05/07/2026 11:03:47
Listen to the news
Neumora Q1 FY26 net loss narrows to $53.5 million
  • Neumora Therapeutics posted a net loss of USD 53.5 million, narrowing from USD 68 million a year earlier, with loss per share improving to USD 0.3 from USD 0.42.
  • R&D expense fell to USD 38.6 million from USD 52.2 million, due to reduced clinical trial costs and lower personnel-related costs.
  • G&A expense dropped to USD 14.3 million from USD 18.8 million on lower personnel-related costs, while cash and cash equivalents slid to USD 147.1 million.
  • KOASTAL-2 and -3 studies of navacaprant in major depressive disorder remain on track for a joint topline readout in Q2 2026, with clinical data for NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in schizophrenia expected in 2H 2026.
  • Management said more than 400 patients were enrolled in each KOASTAL study, with cash expected to fund operations into Q3 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.